Every October, Healthy Lung Month invites us to pause and think about the organs working tirelessly with every breath we take. Founded in awareness by the American Lung Association, this observance has evolved from a simple reminder to quit smoking into a broader call to understand respiratory health at a deeper, more measurable level.
For the 37 million Americans living with chronic lung disease—and the many more who carry unrecognized risk—Healthy Lung Month is a meaningful opportunity. Not to be alarmed, but to be informed. Not to diagnose, but to ask better questions. This October, that conversation includes an emerging frontier: the role of blood biomarkers in understanding lung inflammation, respiratory stress, and overall pulmonary health.
Why Lung Health Deserves Attention
The lungs are among the most environmentally exposed organs in the body. Unlike the liver or kidneys, shielded inside the abdomen, the lungs interface directly with the outside world—taking in approximately 11,000 liters of air every day. That exposure is both essential and consequential.
The Role of Clean Air and Smoking Cessation
Tobacco smoke remains the leading cause of preventable lung disease in the United States. According to the CDC, smoking causes approximately 80–90% of COPD cases and is the primary risk factor for lung cancer. But smoking is not the only hazard. Wildfire smoke, urban air pollution, vaping aerosols, and secondhand exposure each carry documented risks to pulmonary tissue.
Smoking cessation—at any age—remains one of the most impactful steps a person can take for their lung health. Research consistently shows measurable improvements in lung function within weeks of quitting, and a meaningful reduction in inflammatory markers over time.
Common Preventable Lung Conditions
The most prevalent chronic lung conditions share a common thread: they are largely preventable, or at minimum, manageable when identified early.
Chronic Obstructive Pulmonary Disease (COPD) affects an estimated 16 million Americans, with millions more likely undiagnosed. Asthma affects more than 25 million people and spans all age groups. Interstitial pulmonary fibrosis (IPF), while less common, carries a serious prognosis—and earlier awareness can meaningfully shape outcomes. What all of these conditions have in common is that chronic inflammation plays a central role in their progression.
How Healthy Lungs Function
To understand what goes wrong in lung disease, it helps to understand what healthy lungs do exceptionally well.
Gas Exchange and Alveolar Integrity
The lungs’ primary job is gas exchange: pulling oxygen into the bloodstream and releasing carbon dioxide out of it. This happens in the alveoli—tiny air sacs numbering in the hundreds of millions—where the barrier between air and blood is extraordinarily thin. Healthy alveoli are elastic, well-supplied with blood, and coated with surfactant to prevent collapse.
When alveoli are damaged by smoke, inflammation, or infection, their surface area decreases, gas exchange becomes less efficient, and the body must work harder to maintain oxygen levels. This is the structural basis of conditions like emphysema.
Immune Defense and Mucociliary Clearance
Beyond gas exchange, the lungs are a sophisticated immune organ. Airway surfaces are lined with cilia—microscopic hair-like structures—that move a continuous layer of mucus upward and outward, trapping pathogens and particulates before they reach the delicate lower airways. Immune cells called alveolar macrophages stand ready to neutralize inhaled threats.
Chronic smoke exposure paralyzes cilia, impairs macrophage function, and triggers sustained inflammatory responses. Over time, this inflammatory burden becomes the environment in which lung disease develops.
What Drives Lung Disease
Lung disease rarely develops overnight. More often, it is the cumulative result of years of inflammation, immune dysregulation, and environmental insult.
Chronic Inflammation in COPD
COPD is fundamentally an inflammatory condition. In response to cigarette smoke and other irritants, the airways mount an immune response that, over time, becomes self-perpetuating. Neutrophils, macrophages, and T-lymphocytes accumulate in the airways. Protease enzymes are released to break down damaged tissue—but in COPD, this process overshoots, destroying healthy alveolar walls and narrowing the airways in a pattern of progressive, largely irreversible obstruction.
This chronic, systemic inflammation is not contained to the lungs. It circulates, contributing to elevated inflammatory markers measurable in the blood—which is part of why blood biomarkers have relevance in the context of respiratory health monitoring.
Bronchoconstriction in Asthma
Asthma involves a different inflammatory signature. In allergic and eosinophilic asthma—the most common phenotypes—exposure to triggers causes the airways to narrow, swell, and produce excess mucus. The immune cells predominantly involved are eosinophils, a type of white blood cell associated with allergic and inflammatory responses.
Understanding which type of inflammation underlies a person’s asthma has become increasingly important, since some biologic therapies specifically target eosinophil pathways. A complete blood count (CBC) with differential, which quantifies eosinophils, can provide relevant context in monitoring asthma-related inflammation.
Environmental and Occupational Exposures
Beyond smoking, a significant number of lung disease cases are attributable to environmental and occupational exposure. Silica dust (from construction and mining), asbestos (from older buildings and insulation work), coal dust, and chemical fumes are all recognized pulmonary hazards. Workers in these fields carry elevated risk for pneumoconiosis, mesothelioma, and occupational asthma.
Geographic factors matter too. Communities near wildfire corridors or in areas with persistently poor air quality indices bear a disproportionate lung disease burden. For these populations, biomarker monitoring can serve as a meaningful ongoing tool to track how environmental stress is affecting systemic inflammation.
Key Biomarkers Linked to Lung Health
Blood biomarkers do not diagnose lung disease. That point bears repeating clearly: a blood test alone cannot tell you whether you have COPD, asthma, or lung cancer. What biomarkers can do is reflect biological processes—inflammation, clotting activity, genetic risk, immune patterns—that are associated with respiratory conditions. In that role, they serve as supportive, contextual data points that can inform conversations with your healthcare provider.
Here are the key biomarkers that carry relevance for lung health awareness.
CRP and Systemic Inflammation
C-reactive protein (CRP) is a protein produced by the liver in response to inflammation. When the body’s inflammatory response is active—whether from infection, injury, or chronic disease—CRP rises. It is one of the most widely measured systemic inflammation markers in clinical medicine.
In the context of lung health, elevated CRP has been associated with increased inflammatory burden in smokers, individuals with COPD exacerbations, and those with respiratory infections. High-sensitivity CRP (hs-CRP) testing can detect lower levels of chronic inflammation. Levels above 3 mg/L are generally considered to reflect a higher inflammatory state, though interpretation always depends on clinical context.
CRP is not specific to the lungs—it rises in response to many types of inflammation throughout the body. But for individuals who smoke, vape, or have significant environmental exposure, tracking CRP over time may provide a useful window into whether systemic inflammatory activity is present or changing.
D-dimer and Clotting Risk Context
D-dimer is a protein fragment produced when blood clots break down. It is most commonly used in clinical settings as part of the workup for pulmonary embolism (PE)—a blood clot in the lungs—and deep vein thrombosis (DVT).
A normal D-dimer result can be helpful in ruling out acute clotting events in low-risk individuals. An elevated D-dimer, however, is not diagnostic on its own—it can rise with infection, inflammation, recent surgery, pregnancy, and many other conditions. Elevated D-dimer always requires medical evaluation and cannot be self-interpreted as confirmation of a clot.
In the context of lung health awareness, D-dimer is mentioned as a contextual marker—one that reflects the intersection of inflammatory activity and clotting risk that can accompany severe respiratory illness, including COVID-19 pneumonia, COPD exacerbations, and conditions associated with immobility or chronic inflammation.
Alpha-1 Antitrypsin Levels
Alpha-1 antitrypsin (AAT) is a protein produced primarily in the liver that protects lung tissue from enzyme damage. When its levels are genetically low—a condition called alpha-1 antitrypsin deficiency (AATD)—the lungs become vulnerable to progressive enzyme-mediated damage, particularly in individuals who smoke.
AATD is a significant but underdiagnosed cause of emphysema, often presenting in adults aged 30–50—younger than typical COPD onset. Genetic testing for AAT levels and phenotype can identify individuals with this inherited risk long before significant lung damage occurs.
The American Lung Association and the Alpha-1 Foundation recommend testing for AATD in anyone diagnosed with COPD or emphysema, as well as in individuals with unexplained liver disease. For those with a family history of early-onset lung disease, AAT testing may be an informative step toward understanding inherited risk.
CBC and Eosinophils in Asthma
A complete blood count (CBC) with differential provides a breakdown of different white blood cell types circulating in the blood, including eosinophils. In the context of asthma, elevated blood eosinophil counts (typically above 300 cells/μL) are associated with eosinophilic asthma—a phenotype characterized by significant airway inflammation and, often, a stronger response to corticosteroid therapy.
Eosinophil counts are also relevant in conditions like eosinophilic pneumonia and in monitoring response to biologic therapies that target the eosinophil pathway (such as those blocking IL-5 or IL-5 receptor alpha). While a CBC is not a substitute for pulmonary function testing, it can provide complementary information about the type of immune activity occurring in the airways.
For individuals managing asthma or seeking to understand their inflammatory profile, a CBC with differential is a foundational, accessible, and informative test.
Troponin and Right Heart Strain
Troponin is primarily known as a cardiac biomarker—a protein released by heart muscle cells when they are injured or under significant stress. Its mention in a lung health context reflects an important physiological relationship: severe or chronic lung disease can strain the right side of the heart.
In conditions like advanced COPD, severe pulmonary hypertension, or massive pulmonary embolism, the right ventricle—which pumps blood into the lungs—must work against abnormally high resistance. This strain can elevate troponin. A condition called cor pulmonale refers specifically to right heart dysfunction caused by lung disease.
Troponin is not a routine lung health screening marker. However, it is mentioned here as an example of how lung and cardiovascular health are deeply interconnected, and why comprehensive wellness monitoring often spans both systems.
What Lab Testing Can—and Cannot—Tell You
Lab testing is a powerful tool when understood in its proper context. For lung health specifically, it is important to be clear about what blood markers can and cannot accomplish.
Blood Markers vs. Spirometry
Spirometry is the gold-standard functional test for lung disease. By measuring how much air a person can exhale forcefully and how quickly (the FEV1/FVC ratio), spirometry can identify obstruction consistent with COPD (typically an FEV1/FVC ratio below 0.7) and restriction patterns seen in fibrotic disease. It is a direct measure of how the lungs are actually performing.
Blood biomarkers, by contrast, measure systemic signals—inflammation, immune activity, clotting—that may be associated with lung conditions but cannot characterize lung function directly. They are complementary tools, not substitutes. A person could have an elevated CRP and normal spirometry, or normal CRP and impaired spirometry. Each piece of data contributes to a broader picture.
Arterial blood gas (ABG) testing, which measures oxygen and carbon dioxide levels in the blood, provides another layer of functional insight—particularly in assessing hypoxemia in advanced lung disease. ABG is typically administered in clinical settings.
When Imaging (LDCT) Is Recommended
Low-dose computed tomography (LDCT) of the chest is the recommended screening tool for lung cancer in high-risk individuals. The U.S. Preventive Services Task Force (USPSTF) recommends annual LDCT screening for adults aged 50–80 who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
LDCT can detect early nodules and abnormalities before symptoms develop—a meaningful advantage given that lung cancer is far more treatable at early stages. It is important to note that LDCT is a screening and imaging tool; it does not measure inflammation or provide biomarker data. No blood test currently available can substitute for LDCT in lung cancer screening for eligible individuals.
If you meet the LDCT eligibility criteria and have not yet been screened, speaking with your healthcare provider this Healthy Lung Month is a well-timed step.
Who May Benefit From Lung-Focused Testing
Biomarker monitoring is not necessarily appropriate for everyone. But for certain groups, tracking inflammation and related markers can provide meaningful, actionable data.
Smokers and Former Smokers
Current smokers and former smokers carry the highest burden of smoking-attributable lung inflammation. Even after cessation, inflammatory markers may remain elevated for months to years, and the residual risk for COPD, lung cancer, and cardiovascular disease persists.
For this group, tracking CRP over time—alongside clinical check-ins and, when eligible, LDCT screening—can help individuals see measurable evidence of how their body is responding to cessation or continued exposure. Data can be motivating in a way that abstract risk statistics often are not.
Occupational Exposure Groups
Workers with documented exposure to silica, asbestos, coal dust, industrial chemicals, or other respiratory hazards have an elevated baseline inflammatory risk. For these individuals, inflammation monitoring is not anxiety-driven—it is a rational response to known occupational history.
Regular biomarker check-ins, particularly CRP and CBC, can flag changes in systemic inflammatory activity that might otherwise go unnoticed. These data points can also support more productive conversations with occupational health providers.
Adults Over 50 Considering Screening
Adults in the 50–65 age range who have significant smoking history and have not engaged with formal lung cancer screening represent a critical awareness gap. Healthy Lung Month is an appropriate moment to review LDCT eligibility, discuss family history with a provider, and consider whether baseline inflammation monitoring adds value to their overall health picture.
For this group, alpha-1 antitrypsin testing may also be relevant—particularly those diagnosed with COPD at a younger-than-expected age, or those with family members who developed emphysema without significant smoking history.
Taking Ownership of Respiratory Health
Lung health doesn’t have to be reactive. With the right tools and information, it can be part of a proactive, data-informed approach to long-term wellness.
How DTC Inflammation Panels Work
Direct-to-consumer (DTC) lab testing allows individuals to order their own blood tests—including CRP, CBC with differential, D-dimer, and other markers—without waiting for a provider-ordered workup. Results are typically available within days and can be reviewed personally, shared with a healthcare provider, or used to track trends over time.
DTC testing is most valuable when used as a supplement to clinical care, not a replacement for it. It is particularly useful for individuals who want to establish a personal baseline, monitor changes during lifestyle transitions (such as smoking cessation), or prepare for a more informed clinical conversation.
Tracking Biomarker Trends Over Time
A single biomarker result is a snapshot. A series of results over time—taken under consistent conditions—is a trend. And trends are where biomarker data becomes most meaningful.
Watching CRP decline over the months following smoking cessation, for example, provides tangible evidence of the body’s inflammatory recovery. Noticing eosinophil counts that consistently run high might prompt a more detailed conversation about asthma phenotype with an allergist or pulmonologist. Tracking is not about obsessing over individual values—it is about identifying patterns that can guide conversations.
Preparing for Clinical Conversations
One of the most practical uses of DTC biomarker data is as a conversation starter. Walking into a provider appointment with a trend report of your CRP levels, a history of your CBC differentials, or questions prompted by your AAT result puts you in a more engaged, informed position.
Healthcare providers respond well to patients who come prepared. Bringing your own data—framed as questions rather than conclusions—creates a more collaborative clinical dialogue. “My CRP has been running above 3 mg/L for the past several months—is that worth exploring given my smoking history?” is a powerful question. And it’s the kind of question that comes from health ownership.
Closing: Your Lungs, Your Data, Your Conversation
Healthy Lung Month is not about fear. It is about awareness—and the quiet confidence that comes from understanding what your body is doing.
Lung disease is common, often preventable, and frequently silent in its early stages. But the tools available today—from accessible blood biomarkers to LDCT screening to improved smoking cessation support—mean that earlier awareness is more achievable than ever.
This October, consider what you know about your own lung health. If you smoke or have smoked, if you work in an environment with known respiratory hazards, if you live in an area affected by wildfire smoke or poor air quality—you have reason to be curious. Not alarmed. Curious.
Biomarkers won’t give you all the answers. But they can help you ask better questions. And better questions lead to better conversations—and, ultimately, better care.
This article is for educational purposes only. It does not constitute medical advice or replace evaluation by a licensed healthcare professional. Always consult a qualified provider before making decisions based on lab results or health information.
